abstract |
The present invention aims to provide a modified CMV gB protein, which is capable of inducing a high proportion of neutralizing antibodies that exhibit high neutralizing activity against CMV gB protein upon immune induction, and which is useful for preventing and/or treating CMV infection, and a CMV vaccine comprising the same. The modified CMV gB protein of the present invention comprises a modification in the head region, and the ability of the body region to recognize antibodies is improved. |